Skip to Main Content

Advertisement

Skip Nav Destination
photo of Elaine R. Mardis, PhD photo of Lillian L. Siu, MD

Editors-In-Chief


Elaine R. Mardis, PhD
Nationwide Children's Hospital
The Ohio State University

Lillian L. Siu, MD
Princess Margaret Cancer Centre
University of Toronto

Editors-In-Chief

Elaine R. Mardis, PhD
Nationwide Children's Hospital
The Ohio State University
    
Lillian L. Siu, MD
Princess Margaret Cancer Centre
University of Toronto

Editors' Corner

Spotlight on Breast Cancer at Cancer Research Communications and the SABCS

The 2021 San Antonio Breast Cancer Symposium (SABCS) took place December 7–10, 2021 and was attended by thousands of participants, both virtually and in person. The SABCS, which has occurred annually...(read more)

 

Journal Sections

Cancer Research Communications welcomes high-quality research spanning the full spectrum of cancer science and medicine. This open access journal expands the AACR journal portfolio, stimulates the exchange of new ideas and approaches, and provides a rapid publication pathway. The below sections reflect the breadth of this new journal’s scope.

Featured Articles

Molecular and Cellular Biology
Qiujin Shen, Yahui Feng et al.
Although the concept of “myeloid neoplasm continuum” has long been proposed, few comparative genomics studies directly tested this hypothesis. Here we report a multi-modal data analysis of 730 consecutive newly diagnosed patients with primary myeloid neoplasm, along with 462 lymphoid neoplasm cases serving as the ...
Tumor Biology
Galaxia M Rodriguez, Kristianne J.C. Galpin et al.
Epithelial ovarian cancer (EOC) is the most lethal gynecologic cancer with an imperative need for new treatments. Immunotherapy has had marked success in some cancer types; however, clinical trials studying the efficacy of immune checkpoint inhibitors for the treatment of EOC benefited less than 15% of patients. Given ...
Immuno-oncology
Galaxia M Rodriguez, Kristianne J.C. Galpin et al.
Epithelial ovarian cancer (EOC) is the most lethal gynecologic cancer with an imperative need for new treatments. Immunotherapy has had marked success in some cancer types; however, clinical trials studying the efficacy of immune checkpoint inhibitors for the treatment of EOC benefited less than 15% of patients. Given ...
Emerging Technologies and Data Science
Victoria Hoskin, Abdi Ghaffari et al.
The main cause of cancer-associated death is the spread of cancer cells to distant organs. Despite its success in the primary tumor setting, modern chemotherapeutic strategies are rendered ineffective at treating metastatic disease, largely due to the development of resistance. The adaptor protein ezrin has been shown to ...
Therapeutic Research and Development
Kyle A. Cottrell, Luisangely Soto-Torres et al.
The RNA editing enzyme ADAR is an attractive therapeutic target for multiple cancers. Through its deaminase activity, ADAR edits adenosine to inosine in double-stranded RNAs. Loss of ADAR in some cancer cell lines causes activation of the type I IFN pathway and the PKR translational repressor, leading to inhibition of ...
Precision Medicine and Biomarkers
Glenn J. Hanna, Alessandro Villa et al.
Oral leukoplakia is common and may, in some cases, progress to carcinoma. Proliferative leukoplakia is a progressive, often multifocal subtype with a high rate of malignant transformation compared with the more common localized leukoplakia. We hypothesized that the immune microenvironment and gene expression patterns ...
Close Modal

or Create an Account

Close Modal
Close Modal